We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mesoblast Limited | ASX:MSB | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.90% | 2.19 | 2.23 | 2.25 | 2.23 | 2.07 | 2.20 | 19,937,267 | 05:12:07 |
From Mar 2020 to Mar 2025
By Josh Beckerman
Mesoblast Ltd. American depositary receipts surged 25% to $14.70 after hours as the company entered an exclusive worldwide license and collaboration agreement with Novartis AG for Mesoblast's mesenchymal stromal cell product remestemcel-L.
The initial focus will be on treatment of acute respiratory distress syndrome, including that associated with Covid-19.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 19, 2020 17:38 ET (22:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Mesoblast Chart |
1 Month Mesoblast Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
